A

Akari Therapeutics plc
D

AKTX

1.11000
USD
-0.04
(-3.48%)
مغلق
حجم التداول
300
الربح لكل سهم
-0
العائد الربحي
-
P/E
-0
حجم السوق
35,715,771
أصول ذات صلة
A
ACIU
0.02000
(0.82%)
2.46000 USD
A
AXGN
0.160
(1.21%)
13.370 USD
B
BHC
0.00000
(0.00%)
6.78000 USD
BMY
BMY
-0.525
(-1.07%)
48.455 USD
C
CETX
0.01500
(1.21%)
1.25500 USD
C
COCP
-0.05000
(-3.03%)
1.60000 USD
C
CPRX
-0.040
(-0.19%)
20.980 USD
C
CTRM
-0.08000
(-3.35%)
2.31000 USD
C
CTXR
-0.02500
(-1.47%)
1.67000 USD
D
DARE
-0.03500
(-1.34%)
2.58500 USD
E
EVOK
0.03000
(0.67%)
4.48000 USD
I
INMD
0.180
(1.24%)
14.720 USD
K
KTOS
1.100
(1.88%)
59.740 USD
L
LXRX
-0.03000
(-2.67%)
1.09500 USD
O
OPRX
0.385
(2.76%)
14.355 USD
O
OVID
-0.07170
(-10.37%)
0.61980 USD
P
PAAS
-0.135
(-0.46%)
29.140 USD
P
PLAG
0.21000
(11.86%)
1.98000 USD
R
REKR
-0.09000
(-6.72%)
1.25000 USD
R
RGEN
-0.200
(-0.16%)
121.670 USD
S
SCYX
0.02000
(2.78%)
0.74000 USD
S
SHIP
-0.20500
(-2.79%)
7.14500 USD
S
SINT
0.08000
(2.94%)
2.80000 USD
S
SSKN
-0.03000
(-1.48%)
2.00000 USD
T
TLRY
-0.01450
(-2.05%)
0.69170 USD
T
TNXP
4.990
(11.16%)
49.710 USD
T
TTNP
-0.81000
(-15.52%)
4.41000 USD
U
USIO
0.01000
(0.57%)
1.78000 USD
المزيد
الأخبار المقالات

العنوان: Akari Therapeutics plc

القطاع: Healthcare
الصناعة: Biotechnology
Akari Therapeutics PLC is an oncology company developing next-generation antibody-drug conjugates (ADCs) designed around novel, proprietary cancer-killing toxins (payloads). The company believes these novel payloads may have the potential to transform the efficacy and safety outcomes of ADCs as cancer therapies beyond options that are currently available or in development. Its lead product candidate is AKTX-101, a preclinical stage Trop2-targeting ADC that combines PH1 with the Trop2 antibody, which is expressed in the highest number of solid tumor cancer types, including lung, breast, colon and prostate.